Cigna Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CI research report →
Range $302 – $400
Price Chart
About the company
Cigna Group, established in 1792 and headquartered in Bloomfield, Connecticut, provides insurance products and related services across the United States. The company operates through two primary segments. Its Evernorth division offers a comprehensive array of coordinated and specialized health solutions, including pharmacy services, benefits administration, care management and delivery, and advanced intelligence solutions.
- CEO
- Brian C. Evanko
- IPO
- 1982
- Employees
- 66,685
- HQ
- Bloomfield, CT, US
Get TickerSpark's AI analysis on CI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $71.38B
- P/E
- 12.02
- Fwd P/E
- 8.84
- PEG
- -39.13
- P/S
- 0.25
- P/B
- 1.65
- EV/EBITDA
- 7.73
- Div Yield
- 2.27%
- Gross Margin
- 10.26%
- Op Margin
- 3.35%
- Net Margin
- 2.09%
- ROE
- 14.10%
- ROIC
- 7.45%
Latest fiscal year · YoY change
- Revenue
- $274.95B+11.3%
- Gross Profit
- $25.99B+0.1%
- Op Income
- $9.13B
- Net Income
- $5.96B+73.5%
- EPS
- $22.30+82.0%
- OCF Growth
- -7.4%
- FCF Growth
- -6.3%
- 52W High
- $318.05
- 52W Low
- $257.85
- 50D MA
- $288.24
- 200D MA
- $283.12
- Beta
- 0.30
- RSI (14)
- 35
- Avg Volume
- 1.65M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cigna Group beat expectations in Q3, raised 2026 EPS guidance to at least $30.60, and outlined a 2027 bridge that still supports double-digit EPS growth despite transition headwinds in PBM and fewer specialty launch tailwinds.· November 5, 2026
- Q3 adjusted revenue was $73.8 billion, adjusted after-tax earnings were $2.1 billion, and adjusted EPS was $7.98.
- Management raised full-year 2026 adjusted EPS guidance to at least $30.60 and kept segment outlooks strong, including at least $6.9 billion of Evernorth pretax adjusted earnings and at least $4.6 billion for Cigna Healthcare.
- Evernorth specialty and care services posted 15% year-over-year pretax adjusted earnings growth, while Cigna Healthcare also grew pretax adjusted earnings 15% year over year.
- The company said its Signature PBM model is on track for a 1/1/27 launch in Cigna Healthcare fully insured and broader adoption is expected to ramp in 2028.
- Management reiterated 2027 adjusted EPS growth of at least 10% off a roughly $30 run-rate, with $3 billion of gross run-rate savings targeted by 2030 through Accelerate to 1.
Cigna Group reported third-quarter adjusted revenue of $73.8 billion, adjusted after-tax earnings of $2.1 billion, and adjusted EPS of $7.98. Ralph Giacobbe also noted after-tax special item charges of $146 million, or $0.55 per share. Evernorth revenue grew 6% year over year to $63.8 billion, with pretax adjusted earnings of $1.8 billion; Specialty and Care Services pretax adjusted earnings grew 15% year over year to $1.1 billion; Pharmacy Benefit Services pretax adjusted earnings were $765 million. Cigna Healthcare adjusted revenue grew 9% year over year to $11.7 billion, pretax adjusted earnings were $1.2 billion, and the medical care ratio was 85%. Operating cash flow was $2.6 billion, debt to capitalization was 41.8% at quarter-end, and the company repurchased about 900 thousand shares for approximately $250 million. For 2026, management raised adjusted EPS guidance to at least $30.60, reaffirmed Evernorth pretax adjusted earnings of at least $6.9 billion, raised Cigna Healthcare pretax adjusted earnings to at least $4.6 billion, and tightened the full-year MCR outlook around a midpoint of 84.2% plus or minus 25 basis points. Looking to 2027, management said it expects at least 10% adjusted EPS growth off a roughly $30 run-rate, Evernorth earnings up low single digits, Specialty and Care growth near the low end of its 8% to 12% algorithm, and Cigna Healthcare income from operations growth within its 6% to 9% long-term target or above that after adjusting for the ACA exchange exit.
Brian C. Evanko said the quarter showed that Cigna’s deliberately shaped portfolio is working, with core growth across Evernorth and Cigna Healthcare and confidence to raise full-year guidance. He emphasized the company’s Lead to 1 strategy, centered on personalization at scale, affordability, and better outcomes for complex patients through data, clinical expertise, technology, and integrated capabilities. His tone was constructive and confident, while also acknowledging 2027 transition headwinds in PBM and fewer biosimilar/specialty generic launches.
Ann Dennison said the quarter reflected consistent execution, with adjusted revenue of $73.8 billion, adjusted after-tax earnings of $2.1 billion, and adjusted EPS of $7.98. She highlighted Evernorth revenue of $63.8 billion, Cigna Healthcare revenue of $11.7 billion, operating cash flow of $2.6 billion, and debt to capitalization improving to 41.8%, on track to reach about 40% by year-end. She also said third-quarter share repurchases were about $250 million, reaffirmed strong cash generation into Q4, and framed 2027 savings and capital deployment around Accelerate to 1 and a share-repurchase-friendly capital position.
Analysts focused heavily on the new Signature PBM model, asking how adoption would progress, what the 2027 bridge looks like, and whether regulatory changes require extra investment. Management said phase 1 of Signature is complete, phase 2 is active with manufacturer and network-pharmacy contracting underway, and phase 3 adoption is on track for the fully insured Cigna Healthcare book on 1/1/27 with broader Evernorth adoption expected in 2028. They said the Department of Labor rule will be complied with, but the added administrative burden should not require material new spending, and they emphasized that Signature is designed to fit evolving regulation while improving affordability and transparency. Analysts also pressed on the 2027 headwinds, and management clarified that lower employer GLP-1 coverage and industry rebate compression are the main PBM pressures, while the ACA exchange exit creates about a $200 million headwind that they expect to work off over time.
The call showed continued momentum in both core businesses, with earnings growth above expectations, strong retention, and solid new business wins heading into the 2027 selling season. Management sounded confident that specialized capabilities, integrated care, and cost-saving initiatives like Accelerate to 1 can support at least 10% EPS growth in 2027 and at least $45 of EPS by 2030.
Management flagged several 2027 headwinds, including rebate pool compression, lower employer coverage of GLP-1s for weight loss, fewer biosimilar and specialty generic launches, and the ACA exchange exit. They also acknowledged some transition-year pressure in Pharmacy Benefit Services and said 2027 specialty growth should be near the low end of its long-term range, with more meaningful upside from distribution and medical-benefit specialty later in the decade.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 263.50M
- Float Shares
- 262.20M
of shares held by institutions
1,776 13F filers
Buy/sell ratio 1.60. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CI, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 25, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Sep 23, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Buy | Sep 23, 25 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Jared MoskowitzHouse · FL23 | Sell | Mar 23, 26 | Filing → |
| Jared MoskowitzHouse · FL23 | Sell | Mar 23, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Mar 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 13, 26 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Dec 18, 25 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Oct 23, 24 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Apr 22, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Dec 19, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 26.17M | ▲ 414.83K |
| Blackrock, Inc. | 24.11M | ▲ 675.12K |
| Vanguard Capital Management LLC | 17.29M | ▲ 14.68K |
| State Street Corp | 12.96M | ▲ 277.29K |
| Dodge & Cox | 12.26M | ▲ 81.59K |
| Sanders Capital, LLC | 10.10M | ▼ 46.54K |
| Massachusetts Financial Services Co | 9.74M | ▼ 703.41K |
| Geode Capital Management, LLC | 6.82M | ▲ 548.89K |
| Fmr LLC | 6.81M | ▼ 1.21M |
| Vanguard Portfolio Management LLC | 6.31M | ▲ 78.61K |
| Jpmorgan Chase & Co | 5.05M | ▼ 142.62K |
| Morgan Stanley | 3.75M | ▲ 54.19K |
Held by 2,279 ETFs
Biggest fund positions in CI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 3, 26 | Neville Everett | sell | 617 |
| Sep 1, 26 | Evanko Brian C | other | 3,113 |
| Sep 1, 26 | Evanko Brian C | other | 6,716 |
| Aug 31, 26 | Kurian George | other | 108.664 |
| Aug 6, 26 | Holgerson Bryan | other | 0.984 |
| Jul 23, 26 | Holgerson Bryan | other | 0.946 |
| Jul 9, 26 | Holgerson Bryan | other | 0.887 |
| Aug 18, 26 | Jones Nicole S | sell | 2,677 |
| Aug 4, 26 | Jones Nicole S | other | 14,045 |
| Aug 5, 26 | Jones Nicole S | other | 1,301 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CI coverage
Recent articles, reports, and earnings notes.

Elevance beat and raised, so why did the stock trade like something broke?
Elevance didn't get punished for missing the quarter; it got punished because the market no longer trusts the quality of the beat. Raised guidance matters less when Medicaid costs are still rising, membership is slipping, and management is calling 2026 the low point for profitability.

Managed care's rebound looks real, but the easy bull case is early
Health insurers are finally showing signs that the medical-cost spike is easing, but that is not the same thing as a clean, durable margin reset across the group. The better trade still looks selective: some operators are stabilizing, while others remain too expensive or too exposed to unresolved Medicare Advantage and Medicaid pressure.
Want a deeper read on CI?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Cigna Group $CI Shares Purchased by Banco Santander S.A.
defenseworld.net · Nov 20
The Cigna Group Deepens Community Impact Strategy, Adds New Commitment Supporting People with Complex Health Conditions
prnewswire.com · Nov 19
5 HMO Stocks to Watch Amid Sound Membership Base, Tech Innovation
zacks.com · Nov 17
Bull Market ‘Has Room to Run': 10 Stocks to Buy Now
youtube.com · Nov 16
Cigna Group $CI Shares Purchased by Allworth Financial LP
defenseworld.net · Nov 15
Cigna Group $CI Shares Bought by Aberdeen Group plc
defenseworld.net · Nov 14
Banyan Capital Management Inc. Makes New $17.64 Million Investment in Cigna Group $CI
defenseworld.net · Nov 12
Cigna (CI) Recently Broke Out Above the 20-Day Moving Average
zacks.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.